Skip to menu Skip to content Skip to footer

2025

Journal Article

Oncologist and General Practitioner Perspectives of Shared Care for Colorectal Cancer Survivors: A Qualitative Study

Lisy, Karolina, Tieu, Matthew, Gore, Claire, Schofield, Penelope, Chan, Raymond J., Emery, Jon, Martin, Andrew, De Abreu Lourenco, Richard and Jefford, Michael (2025). Oncologist and General Practitioner Perspectives of Shared Care for Colorectal Cancer Survivors: A Qualitative Study. Psycho-Oncology, 34 (7) e70223, 7. doi: 10.1002/pon.70223

Oncologist and General Practitioner Perspectives of Shared Care for Colorectal Cancer Survivors: A Qualitative Study

2025

Journal Article

INTEGRATE pooled phase II/III results are robust to post-progression switching and winner’s curse

Soon, Yu Yang, Sjoquist, Katrin, Marschner, Ian C, Schou, I Manjula, Pavlakis, Nick, Goldstein, David, Shitara, Kohei, Stockler, Martin R, Simes, John and Martin, Andrew J (2025). INTEGRATE pooled phase II/III results are robust to post-progression switching and winner’s curse. JNCI Cancer Spectrum, 9 (4) pkaf053. doi: 10.1093/jncics/pkaf053

INTEGRATE pooled phase II/III results are robust to post-progression switching and winner’s curse

2025

Conference Publication

177 Lu-PSMA-617 with ipilimumab (ipi) and nivolumab (nivo) in metastatic castration-resistant prostate cancer (mCRPC): An investigator-initiated phase 2 trial (EVOLUTION; ANZUP2001)

Sandhu, Shahneen, Subramaniam, Shalini, Thomas, Hayley, Tan, Thean Hsiang, Goh, Jeffrey C., Dhiantravan, Nattakorn, Weickhardt, Andrew James, Joshua, Anthony M., Kirkwood, Ian David, Lee, Sze Ting, Gedye, Craig, Nguyen, Andrew, Pattison, David A., Alipour, Ramin, Francis, Roslyn J., Hofman, Michael S., Martin, Andrew James, Stockler, Martin R., Davis, Ian D., Emmett, Louise and The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) (2025). 177 Lu-PSMA-617 with ipilimumab (ipi) and nivolumab (nivo) in metastatic castration-resistant prostate cancer (mCRPC): An investigator-initiated phase 2 trial (EVOLUTION; ANZUP2001). 2025 ASCO Annual Meeting I, Chicago, IL, United States, 30 May - 3 June 2025. Alexandria, VA, United States: American Society of Clinical Oncology. doi: 10.1200/jco.2025.43.16_suppl.5016

177 Lu-PSMA-617 with ipilimumab (ipi) and nivolumab (nivo) in metastatic castration-resistant prostate cancer (mCRPC): An investigator-initiated phase 2 trial (EVOLUTION; ANZUP2001)

2025

Conference Publication

Association of circulating immune and metabolic markers with clinical outcomes in the ENZAMET trial (ANZUP 1304)

Horvath, Lisa, Lin, Hui-Ming, Davis, Ian D., Martin, Andrew James, Yeung, Nicole, Kim, Rachel MN, Portman, Neil, Joshua, Anthony M., McJannett, Margaret Mary, Subhash, Vinod, Yip, Sonia, North, Scott A., McDermott, Raymond S., Chi, Kim N., Stockler, Martin R., Sweeney, Christopher and The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) (2025). Association of circulating immune and metabolic markers with clinical outcomes in the ENZAMET trial (ANZUP 1304). 2025 ASCO Annual Meeting, Chicago, IL, United States, 30 May - 3 June 2025. Alexandria, VA, United States: American Society of Clinical Oncology. doi: 10.1200/jco.2025.43.16_suppl.5093

Association of circulating immune and metabolic markers with clinical outcomes in the ENZAMET trial (ANZUP 1304)

2025

Conference Publication

Clonal hematopoiesis (CH) in participants with metastatic castration-resistant prostate cancer (mCRPC) receiving 177 Lu-PSMA-617 or cabazitaxel: An exploratory post-hoc analysis of a randomized phase II trial (TheraP; ANZUP 1603)

Munzur, Aslı Doğa, Herberts, Cameron, Kwan, Edmond Michael, Emmett, Louise, Sandhu, Shahneen, Buteau, James Patrick, Iravani, Amir, Joshua, Anthony M., Francis, Roslyn J., Lee, Sze Ting, Scott, Andrew Mark, Martin, Andrew James, Stockler, Martin R., Zhang, Alison Yan, Williams, Scott G., Bacon, Jack V.W., Azad, Arun, Davis, Ian D., Hofman, Michael S., Wyatt, Alexander William and The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) (2025). Clonal hematopoiesis (CH) in participants with metastatic castration-resistant prostate cancer (mCRPC) receiving 177 Lu-PSMA-617 or cabazitaxel: An exploratory post-hoc analysis of a randomized phase II trial (TheraP; ANZUP 1603). 2025 ASCO Annual Meeting I, Chicago, IL, United States, 30 May - 3 June 2025. Alexandria, VA, United States: American Society of Clinical Oncology. doi: 10.1200/jco.2025.43.16_suppl.5020

Clonal hematopoiesis (CH) in participants with metastatic castration-resistant prostate cancer (mCRPC) receiving 177 Lu-PSMA-617 or cabazitaxel: An exploratory post-hoc analysis of a randomized phase II trial (TheraP; ANZUP 1603)

2025

Conference Publication

Predictive and prognostic value of baseline PSMA-PET total tumor volume and SUV mean within ENZA-p, a randomized phase II trial of enzalutamide versus enzalutamide plus [ 177 Lu] Lu-PSMA-617 (ANZUP1901)

Emmett, Louise, Papa, Nathan, Subramaniam, Shalini, Crumbaker, Megan, Joshua, Anthony M., Nguyen, Andrew, Weickhardt, Andrew James, Lee, Sze Ting, Ng, Siobhan, Francis, Roslyn J., Goh, Jeffrey C., Pattison, David A., Tan, Thean Hsiang, Kirkwood, Ian David, Hofman, Michael S., Sandhu, Shahneen, Martin, Andrew James, Thomas, Hayley, Davis, Ian D., Stockler, Martin R. and The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) (2025). Predictive and prognostic value of baseline PSMA-PET total tumor volume and SUV mean within ENZA-p, a randomized phase II trial of enzalutamide versus enzalutamide plus [ 177 Lu] Lu-PSMA-617 (ANZUP1901). 2025 ASCO Annual Meeting, Chicago, IL, United States, 30 May - 3 June 2025. Alexandria, VA, United States: American Society of Clinical Oncology. doi: 10.1200/jco.2025.43.16_suppl.5011

Predictive and prognostic value of baseline PSMA-PET total tumor volume and SUV mean within ENZA-p, a randomized phase II trial of enzalutamide versus enzalutamide plus [ 177 Lu] Lu-PSMA-617 (ANZUP1901)

2025

Journal Article

Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial

Kwan, Edmond M., Ng, Sarah W. S., Tolmeijer, Sofie H., Emmett, Louise, Sandhu, Shahneen, Buteau, James P., Iravani, Amir, Joshua, Anthony M., Francis, Roslyn J., Subhash, Vinod, Lee, Sze-Ting, Scott, Andrew M., Martin, Andrew J., Stockler, Martin R., Donnellan, Grainne, Annala, Matti, Herberts, Cameron, Davis, Ian D., Hofman, Michael S., Azad, Arun A., Wyatt, Alexander W., Akhurst, Tim, Alipour, Ramin, Bailey, Dale L., Banks, Patricia, Beaulieu, Alexis, Campbell, Louise, Chua, Wei, Crumbaker, Megan ... Zhang, Alison Y. (2025). Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial. Nature Medicine, 2025 (8), 1-15. doi: 10.1038/s41591-025-03704-9

Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial

2025

Journal Article

Association of the circulating lipid panel, PCPro, with clinical outcomes in metastatic hormone-sensitive prostate cancer: post-hoc analysis of the ENZAMET Phase 3 randomised trial (ANZUP 1304)

Lin, H.-M., Scheinberg, T., Portman, N., Kim, R.M.N., Mellor, R., Hunyh, K., Faulkner, A.N., Mellett, N.A., Davis, I.D., Martin, A., Sullivan, D., Joshua, A., McJannett, M., Subhash, V., Yip, S., Azad, A.A., Marschner, I.C., North, S.A., McDermott, R.S., Chi, K.N., Stockler, M.R., Sweeney, C.J., Meikle, P.J. and Horvath, L.G. (2025). Association of the circulating lipid panel, PCPro, with clinical outcomes in metastatic hormone-sensitive prostate cancer: post-hoc analysis of the ENZAMET Phase 3 randomised trial (ANZUP 1304). Annals of Oncology, 36 (9), 1068-1077. doi: 10.1016/j.annonc.2025.05.529

Association of the circulating lipid panel, PCPro, with clinical outcomes in metastatic hormone-sensitive prostate cancer: post-hoc analysis of the ENZAMET Phase 3 randomised trial (ANZUP 1304)

2025

Journal Article

Can we use viral receptor mapping and particle deposition models to predict the clinical severity of novel airborne pathogens?

Pillay, Kineshta, Marr, Linsey C., Henriques, Andre, Martin, Andrew R., Prussin, Aaron J., Aleixo, Luis, Andreini, Marco, Mounet, Nicolas, Finlay, Warren H. and Tang, Julian W. (2025). Can we use viral receptor mapping and particle deposition models to predict the clinical severity of novel airborne pathogens?. Clinical Microbiology and Infection, 31 (4), 503-505. doi: 10.1016/j.cmi.2024.11.005

Can we use viral receptor mapping and particle deposition models to predict the clinical severity of novel airborne pathogens?

2025

Journal Article

Targeted Long-Read Sequencing as a Single Assay Improves the Diagnosis of Spastic-Ataxia Disorders

Rudaks, Laura Ivete, Stevanovski, Igor, Yeow, Dennis, Reis, Andre L. M., Chintalaphani, Sanjog R., Cheong, Pak Leng, Gamaarachchi, Hasindu, Worgan, Lisa, Ahmad, Kate, Hayes, Michael, Hannaford, Andrew, Kim, Samuel, Fung, Victor S. C., Halmagyi, Gabor M., Martin, Andrew, Manser, David, Tchan, Michel, Ng, Karl, Kennerson, Marina L., Deveson, Ira W. and Kumar, Kishore Raj (2025). Targeted Long-Read Sequencing as a Single Assay Improves the Diagnosis of Spastic-Ataxia Disorders. Annals of Clinical and Translational Neurology, 12 (4), 832-841. doi: 10.1002/acn3.70008

Targeted Long-Read Sequencing as a Single Assay Improves the Diagnosis of Spastic-Ataxia Disorders

2025

Conference Publication

Overall survival and quality of life with [ <sup>177</sup> Lu] Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in poor-risk, metastatic, castration-resistant prostate cancer in ENZA-p (ANZUP 1901)

Emmett, Louise, Subramaniam, Shalini, Crumbaker, Megan, Nguyen, Andrew, Joshua, Anthony M., Weickhardt, Andrew James, Lee, Sze Ting, Ng, Siobhan, Francis, Roslyn J., Goh, Jeffrey C., Pattison, David A., Tan, Thean Hsiang, Kirkwood, Ian David, Sandhu, Shahneen, Zhang, Alison Yan, Hofman, Michael S., Thomas, Hayley, Martin, Andrew James, Davis, Ian D., Stockler, Martin R. and The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) (2025). Overall survival and quality of life with [ 177 Lu] Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in poor-risk, metastatic, castration-resistant prostate cancer in ENZA-p (ANZUP 1901). 2025 ASCO Genitourinary Cancers Symposium, San Francisco, CA United States, 13-15 February 2025. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2025.43.5_suppl.17

Overall survival and quality of life with [ <sup>177</sup> Lu] Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in poor-risk, metastatic, castration-resistant prostate cancer in ENZA-p (ANZUP 1901)

2025

Journal Article

Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial

Emmett, Louise, Subramaniam, Shalini, Crumbaker, Megan, Joshua, Anthony M, Sandhu, Shahneen, Nguyen, Andrew, Weickhardt, Andrew, Lee, Sze-Ting, Ng, Siobhan, Francis, Roslyn J, Goh, Jeffrey C, Pattison, David A, Tan, Thean Hsiang, Kirkwood, Ian D, Gedye, Craig, Rutherford, Natalie K, Kumar, Aravind S Ravi, Pook, David, Ramdave, Shakher, Nadebaum, David P, Voskoboynik, Mark, Redfern, Andrew D, Macdonald, William, Krieger, Laurence, Schembri, Geoff, Chua, Wei, Lin, Peter, Horvath, Lisa, Bastick, Patricia ... Bills, Madison (2025). Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial. The Lancet Oncology, 26 (3), 291-299. doi: 10.1016/s1470-2045(25)00009-9

Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial

2025

Journal Article

Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304)

Conduit, Ciara, Inderjeeth, Andrisha-Jade, Allen, Raymond, Martin, Andrew J., Parulekar, Wendy, Mulroe, Eibhlin, McJannett, Margaret, Zielinski, Robert R., Thomson, Alastair, Tan, Thean Hsiang, Sandhu, Shahneen K., Reaume, M. Neil, Pook, David W., North, Scott A., Marx, Gavin M., Joshua, Anthony, Horvath, Lisa, McDermott, Ray, Chowdhury, Simon, Chi, Kim N., Zhang, Alison Y., Stockler, Martin R., Davis, Ian D., Sweeney, Christopher J. and on behalf of ANZUP Cancer Trials Group (2025). Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304). Future Oncology, 21 (6), 627-636. doi: 10.1080/14796694.2024.2440277

Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304)

2025

Journal Article

Balancing precision and affordability in assessing infant development in large-scale mortality trials: Secondary analysis of a randomised controlled trial

Robledo, Kristy P., Rieger, Ingrid, Finlayson, Sarah, Tarnow-Mordi, William and Martin, Andrew J. (2025). Balancing precision and affordability in assessing infant development in large-scale mortality trials: Secondary analysis of a randomised controlled trial. Archives of Disease in Childhood: Fetal and Neonatal Edition, 110 (4), F409-F414. doi: 10.1136/archdischild-2024-327762

Balancing precision and affordability in assessing infant development in large-scale mortality trials: Secondary analysis of a randomised controlled trial

2025

Journal Article

Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial

Emmett, Louise, Papa, Nathan, Subramaniam, Shalini, Crumbaker, Megan, Nguyen, Andrew, Joshua, Anthony M, Sandhu, Shahneen, Weickhardt, Andrew, Lee, Sze-Ting, Ng, Siobhan, Francis, Roslyn J, Goh, Jeffrey C, Pattison, David A, Tan, Thean Hsiang, Kirkwood, Ian D, Ayati, Narjess, Niu, Claire, Hofman, Michael S, Martin, Andrew James, Thomas, Hayley, Davis, Ian D and Stockler, Martin R (2025). Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial. The Lancet Oncology, 26 (9), 1168-1177. doi: 10.1016/S1470-2045(25)00339-0

Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial

2024

Journal Article

Understanding regional aerosol deposition in pediatric airways during oral breathing: Insights from computational modeling

Pillay, Kineshta, Finlay, Warren H. and Martin, Andrew R. (2024). Understanding regional aerosol deposition in pediatric airways during oral breathing: Insights from computational modeling. Journal of Aerosol Science, 182 106438. doi: 10.1016/j.jaerosci.2024.106438

Understanding regional aerosol deposition in pediatric airways during oral breathing: Insights from computational modeling

2024

Journal Article

INTEGRATE IIa Phase III Study: Regorafenib for refractory advanced gastric cancer

Pavlakis, Nick, Shitara, Kohei, Sjoquist, Katrin, Martin, Andrew, Jaworski, Anthony, Tebbutt, Niall, Bang, Yung-Jue, Alcindor, Thierry, O'Callaghan, Chris, Strickland, Andrew, Rha, Sun Young, Lee, Keun-Wook, Kim, Jin-Soo, Bai, Li-Yuan, Hara, Hiroki, Oh, Do-Youn, Yip, Sonia, Zalcberg, John, Price, Tim, Simes, John and Goldstein, David (2024). INTEGRATE IIa Phase III Study: Regorafenib for refractory advanced gastric cancer. Journal of Clinical Oncology, 43 (4), 453-463. doi: 10.1200/jco.24.00055

INTEGRATE IIa Phase III Study: Regorafenib for refractory advanced gastric cancer

2024

Conference Publication

EV430/#358  Benefit-harm trade-off for groin node dissection versus groin ultrasound monitoring to reduce the risk of surgery-related morbidity in vulvar cancer – a decision-tree analysis

Obermair, Andreas, West, Zoe, Baxter, Eva, Condous, George, Hacker, Neville, Lord, Sally, Mccarthy, Sandie, Janda, Monika, Tuffaha, Haitham, Hayes, Sandi, Disipio, Tracey, Mellon, Anne, Gebski, Val, Mcnally, Orla and Martin, Andrew (2024). EV430/#358  Benefit-harm trade-off for groin node dissection versus groin ultrasound monitoring to reduce the risk of surgery-related morbidity in vulvar cancer – a decision-tree analysis. IGCS 2024 Annual Meeting, Dublin, Ireland, 16-18 October 2024. London, United Kingdom: BMJ Group. doi: 10.1136/ijgc-2024-igcs.551

EV430/#358  Benefit-harm trade-off for groin node dissection versus groin ultrasound monitoring to reduce the risk of surgery-related morbidity in vulvar cancer – a decision-tree analysis

2024

Journal Article

Lu-177 PSMA vs comparator treatments and survival in metastatic castration-resistant prostate cancer

Soon, Yu Yang, Marschner, Ian C., Schou, Manjula, Hofman, Michael S., Emmett, Louise, Davis, Ian D., Stockler, Martin R. and Martin, Andrew J. (2024). Lu-177 PSMA vs comparator treatments and survival in metastatic castration-resistant prostate cancer. JAMA Network Open, 7 (9) e2433863, 1-13. doi: 10.1001/jamanetworkopen.2024.33863

Lu-177 PSMA vs comparator treatments and survival in metastatic castration-resistant prostate cancer

2024

Journal Article

Survival of men with metastatic hormone-sensitive prostate cancer and adrenal-permissive HSD3B1 inheritance

Sharifi, Nima, Diaz, Robert, Lin, Hui-Ming, Roberts, Evan, Horvath, Lisa G., Martin, Andrew, Stockler, Martin R., Yip, Sonia, Subhash, Vinod V., Portman, Neil, Davis, Ian D. and Sweeney, Christopher J. (2024). Survival of men with metastatic hormone-sensitive prostate cancer and adrenal-permissive HSD3B1 inheritance. Journal of Clinical Investigation, 134 (18) e183583, 1-9. doi: 10.1172/jci183583

Survival of men with metastatic hormone-sensitive prostate cancer and adrenal-permissive HSD3B1 inheritance